Juno Therapeutics

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.
Company Growth (employees)
Type
Public
HQ
Seattle, US
Founded
2013
Size (employees)
548 (est)+3%
Juno Therapeutics was founded in 2013 and is headquartered in Seattle, US

Key People/Management at Juno Therapeutics

Hans Bishop

Hans Bishop

CEO

Juno Therapeutics Office Locations

Juno Therapeutics has offices in Seattle, Washington, Bothell, Waltham and in 3 other locations
Seattle, US (HQ)
300 307 Westlake Ave N
Show all (7)

Juno Therapeutics Financials and Metrics

Juno Therapeutics Financials

Juno Therapeutics's revenue was reported to be $19.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

19.3 m

Net income (Q1, 2017)

(82.2 m)

EBIT (Q1, 2017)

(84.3 m)

Market capitalization (17-Oct-2017)

4.5 b

Cash (31-Mar-2017)

205.7 m
Juno Therapeutics's current market capitalization is $4.5 b.
USDFY, 2015FY, 2016

Revenue

18.2 m79.4 m

Revenue growth, %

336%

R&D expense

46.2 m264.3 m

General and administrative expense

4.2 m70.7 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

12.5 m1.6 m9.8 m27.6 m20.8 m19.3 m

R&D expense

57.8 m60.2 m11.5 m73.7 m72.3 m60.9 m82.9 m

General and administrative expense

6.7 m14.9 m13.6 m16 m16.8 m18.4 m20.7 m

Operating expense total

64.5 m75.1 m25.1 m89.7 m89.1 m79.3 m103.7 m
USDFY, 2015FY, 2016

Cash

252.4 m187.9 m

Accounts Receivable

315 k13.3 m

Inventories

8.4 m26.5 m

Current Assets

951.8 m772.3 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

164.2 m39.5 m569.1 m316 m285.3 m223.4 m205.7 m

Accounts Receivable

9.3 m10.6 m8.8 m

Current Assets

400.7 m307.8 m1.2 b956 m974.6 m844.8 m779.5 m

PP&E

15.4 m28.7 m36.9 m45 m51.5 m57.7 m102.5 m
USDFY, 2015FY, 2016

Net Income

(51.8 m)(245.6 m)

Depreciation and Amortization

2 k14.2 m

Accounts Receivable

33 k(13 m)

Accounts Payable

(2.7 m)3.7 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(65 m)(66 m)(23.2 m)(71.1 m)(64.8 m)(56.9 m)(82.2 m)

Depreciation and Amortization

1 m

Accounts Receivable

9.3 m10.6 m8.8 m

Accounts Payable

(27 k)1.9 m3 m2.2 m3.2 m3.7 m3.2 m
USDY, 2017

Revenue/Employee

35.8 k

Financial Leverage

1.3 x
Show all financial metrics

Juno Therapeutics Operating Metrics

Juno Therapeutics's Patent Applications was reported to be 481 in FY, 2016
FY, 2016

Patents (US)

72

Patent Applications

481

Patents (foreign)

86
Show all operating metrics

Juno Therapeutics Market Value History

Traffic Overview of Juno Therapeutics

Juno Therapeutics Online and Social Media Presence

Juno Therapeutics Company Life and Culture

You may also be interested in